Quest Diagnostics Infectious Disease, Inc. Sustainability Profile
Quest Diagnostics Infectious Disease, Inc., a prominent player in the diagnostics industry, is headquartered in the United States. Founded in 1967, the company has established itself as a leader in infectious disease testing, offering a comprehensive range of laboratory services that cater to healthcare providers and patients alike. With a focus on advanced diagnostic solutions, Quest Diagnostics provides unique products such as molecular testing and serology assays, which are crucial for the accurate detection of various infectious diseases. The company operates extensively across major regions in the US, ensuring accessibility and reliability in its services. Recognised for its commitment to innovation and quality, Quest Diagnostics has achieved significant milestones, including numerous partnerships and advancements in testing technology, solidifying its market position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Quest Diagnostics Infectious Disease, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Quest Diagnostics Infectious Disease, Inc.'s score of 11 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Quest Diagnostics Infectious Disease, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Quest Diagnostics Incorporated, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges specific to Quest Diagnostics Infectious Disease, Inc. However, emissions data and performance metrics may be inherited from its parent company, Quest Diagnostics Incorporated, which has been active in sustainability initiatives. While specific figures for Scope 1, 2, or 3 emissions are not provided, the absence of data suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. The lack of specific emissions data and reduction targets indicates a potential area for development in their environmental commitments. In summary, Quest Diagnostics Infectious Disease, Inc. currently lacks detailed emissions data and specific climate commitments, relying on the broader sustainability efforts of its parent company, Quest Diagnostics Incorporated.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 83,929,000 | 00,000,000 | - | 000,000,000 | 000,000,000 |
| Scope 2 | 145,724,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 41,299,000 | 00,000,000 | 00,000,000 | - | 000,000,000 |
How Carbon Intensive is Quest Diagnostics Infectious Disease, Inc.'s Industry?
How Carbon Intensive is Quest Diagnostics Infectious Disease, Inc.'s Location?
Quest Diagnostics Infectious Disease, Inc.'s Scope 3 Categories Breakdown
Quest Diagnostics Infectious Disease, Inc.'s Scope 3 emissions, which increased significantly last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 62% of Scope 3 emissions.
Top Scope 3 Categories
Quest Diagnostics Infectious Disease, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Quest Diagnostics Infectious Disease, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
